Making the undruggable druggable
Unlocking challenging drug targets for the development of next-generation therapeutics
Selected Collaborations
It all starts with the drug target.
The majority of drug targets are so-called membrane proteins, and these are inherently unstable and challenging to investigate. Or so they were, until now.
Our proprietary Salipro® technology stabilizes membrane proteins in their native forms, enabling them to be employed in drug discovery programs for therapeutic antibodies or small molecule drugs. Through our in-house and partnered pipelines, we drive the discovery of novel drugs.
Pushing drug development forward together
We work with top-tier pharma and biotech partners to unlock drug targets for drug development programs.
Pipeline
We are driving forward drug development in our partnered as well as internal pipelines.
News
New Executive Interview: Salipro Biotech & Bio-Rad Featured in Drug Development & Delivery
2025-05-12
Out now - an executive interview with Francisco Ylera from Bio-Rad Laboratories and Jens Frauenfeld from Salipro Biotech published in Drug Development & Delivery features a straightforward solution for tackling one of biotech's toughest challenges: discovering therapeutic antibodies against complex transmembrane proteins.
In a short timeframe, the collaboration has already yielded exciting results: novel human antibodies targeting the challenging chemokine receptor, CXCR4. These antibodies demonstrate:
Higher affinity than the current benchmark antibody ulocuplumab
Enhanced functionality in cell-based assays
Potential new mechanisms of action for CXCR4-mediated therapeutics
This success is enabled by combining the Salipro® platform for stabilizing native membrane proteins with Bio-Rad's Pioneer™ Antibody Discovery Platform. This synergy overcomes critical bottlenecks, accelerating the discovery of potentially more effective therapeutics.
We’re making this approach applicable to a wide range of challenging membrane protein targets. Read the full interview to learn more about how we are accelerating antibody discovery.
Salipro® unlocks Structural Insights into Key Metabolic Transporter SLC33A1
2025-04-25
Great science enabled by Salipro®: A new study published in Cell Discovery, details the cryo-EM structure of the human acetyl-CoA transporter SLC33A1, offering mechanistic insights crucial for targeting diseases like neurodegeneration and cancer.
Understanding how SLC33A1 recognizes and transports its substrate is vital for developing novel therapeutics. With the Salipro® platform, the authors successfully stabilized human SLC33A1, enabling researchers to determine its 3.5 Å cryo-EM structure complexed with acetyl-CoA.
Key implications of this research:
Advances fundamental understanding of SLC33A1's vital physiological functions.
Provides a structural blueprint with significant potential to guide drug development for conditions including neurodegenerative disorders, aging-related diseases, and certain cancers.
Read the full article here: D. Zhou, et al., Mechanistic insights into the acetyl-CoA recognition by SLC33A1. Cell Discov. 11, 36 (2025).
Salipro Biotech at PEGS Boston, May 12-16!
2025-04-23
Salipro Biotech will be in PEGS Boston, taking place on May 12-16, ready to connect!
Our Business Development Director, Peter Jahnmatz, will present a poster highlighting the latest advancements on the Salipro® platform for the stabilization of challenging membrane protein targets for drug discovery applications.
If you are attending PEGS Boston, make sure to stop by Peter's poster to say hi and discover how the Salipro® technology can accelerate your pipeline programs targeting difficult membrane proteins such as GPCRs, ion channels and SLC transporters.
We look forward to connecting with fellow researchers and industry leaders at PEGS Boston!
For more information on PEGS Boston, please visit the website: https://www.pegsummit.com